Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Roussou

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|February 27, 2016
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myelomaFlora Zagouri, Maria Roussou, Efstathios Kastritis, et al.
American Journal of Hematology|May 9, 2012
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agentsAnna Tasidou, Maria Roussou, Evangelos Terpos, et al.
Clinical Lymphoma & Myeloma|September 1, 2009
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factorsMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
Ejhaem|January 27, 2025
Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myelomaEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Blood|April 21, 2012
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosisEfstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
Annals of Hematology|April 21, 2020
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myelomaMagdalini Migkou, Irit Avivi, Maria Gavriatopoulou, et al.
Viruses|March 30, 2023
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective StudyVassiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 4, 2015
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple MyelomaGerasimos-Petros Papassotiriou, Efstathios Kastritis, Maria Gkotzamanidou, et al.
American Journal of Hematology|October 1, 2010
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trialEvangelos Eleutherakis-Papaiakovou, Evangelos Kostis, Magda Migkou, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|February 27, 2016
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myelomaFlora Zagouri, Maria Roussou, Efstathios Kastritis, et al.
American Journal of Hematology|May 9, 2012
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agentsAnna Tasidou, Maria Roussou, Evangelos Terpos, et al.
Clinical Lymphoma & Myeloma|September 1, 2009
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factorsMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
Ejhaem|January 27, 2025
Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myelomaEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Blood|April 21, 2012
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosisEfstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
Annals of Hematology|April 21, 2020
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myelomaMagdalini Migkou, Irit Avivi, Maria Gavriatopoulou, et al.
Viruses|March 30, 2023
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective StudyVassiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 4, 2015
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple MyelomaGerasimos-Petros Papassotiriou, Efstathios Kastritis, Maria Gkotzamanidou, et al.
American Journal of Hematology|October 1, 2010
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trialEvangelos Eleutherakis-Papaiakovou, Evangelos Kostis, Magda Migkou, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
Pageof 8